NFKB1 and Alzheimer disease: This class of NF-κB signaling pathway inhibitors function by downregulating the activity of NF-κB, inhibiting the expression of neurotoxic cytokines and chemokines, and attenuating Aβ production to block the progression of AD (Sivandzade et al., 2019).